Disclosures for "Characteristics and Disease Burden of Patients With Idiopathic Hypersomnia With and Without Long Sleep Time: The Real-World Idiopathic Hypersomnia Outcomes Study (ARISE) ")
-
Dr. Schneider has received personal compensation for serving as an employee of Alphabet, Inc. Dr. Schneider has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for San Fransisco Public Defender's Office. Dr. Schneider has received intellectual property interests from a discovery or technology relating to health care.
-
Ms. Stevens has stock in Jazz Pharmaceuticals.
-
Dr. Husain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Husain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BlackThorn Pharmaceuticals. Dr. Husain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuiticals. Dr. Husain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Marinus Pharmaceuticals. Dr. Husain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis Pharmaceuitcals. Dr. Husain has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Pharmaceuticals. Dr. Husain has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Husain has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Husain has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for International Federation of Clinical Neurophysiology. Dr. Husain has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for American Clinical Neurophysiology Society. Dr. Husain has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. The institution of Dr. Husain has received research support from Marinus Pharmaecuticals. Dr. Husain has received publishing royalties from a publication relating to health care. Dr. Husain has received publishing royalties from a publication relating to health care. Dr. Husain has received publishing royalties from a publication relating to health care. Dr. Husain has a non-compensated relationship as a Vice Chair of CNP MOC committee with American Board of Psychiatry and Neurology that is relevant to AAN interests or activities.
-
The institution of Ms. Ito has received research support from Jazz Pharmaceuticals.
-
Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has received stock or an ownership interest from D F.
-
Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has received stock or an ownership interest from Jazz pharma.